Congress is being praised for its bipartisan efforts in its markup of the user fee reauthorization. The current user fee program will expire in September.
AdvaMed seems happy with this week's developments, as president and CEO Stephen Ubl stated, "Mark up is an important milestone in the reauthorization process, and we are encouraged by the bipartisan support this legislation has received."
"The user fee agreement recently reached between the agency and the medical technology industry is a potential game-changer that could help accelerate the development and approval of safe and effective treatments and diagnostics," Ubl stated in an association release.
Maria Fontanazza is managing editor at UBM Canon. Follow her on Twitter @MariaFontanazza.